Jove
Visualize
Contact Us

Related Experiment Videos

[Chemotherapy for prostate cancer].

Naoki Itoh1

  • 1Department of Urology, Sapporo Medical University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 18, 2005
PubMed
Summary

Chemotherapy for hormone refractory prostate cancer (HRPC) offers palliative benefits and can improve survival. While some treatments show high response rates, careful consideration of toxicity and patient quality of life is essential for HRPC management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraspecific Variation in the Characteristics of Cryptocaryon irritans Isolated in Japan.

Journal of fish diseases·2026
Same author

The Synergy of Cognitive Impairment and Physical Frailty on Fall Risk in Older Adults: A Memory Clinic-Based Study.

Geriatrics & gerontology international·2026
Same author

Elucidation of the life cycle of Galactosomum nagasakiense (Heterophyidae), the causative parasite of trematode whirling disease in marine fish, with discovery of congeneric species in the gastropod first intermediate host Cerithium dialeucum.

Parasitology international·2025
Same author

Intervention Effects of the Holistic Physio-Cognitive Rehabilitation for Alzheimer Disease and Mild Cognitive Impairment.

Annals of geriatric medicine and research·2025
Same author

Unlocking the Value of Neuropsychological Assessments in Rehabilitation: Perspectives from Persons with Dementia and Their Caregivers.

Current therapeutic research, clinical and experimental·2025
Same author

Genome of Kumamoto Oyster <i>Crassostrea sikamea</i> Provides Insights Into Bivalve Evolution and Environmental Adaptation.

Evolutionary applications·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Urology

Background:

  • The clinical significance of chemotherapy for hormone refractory prostate cancer (HRPC) remains debated.
  • Existing treatments like mitoxantrone/prednisone offer palliative benefits and are well-tolerated in elderly patients.
  • Estramustine and taxane regimens show high PSA response rates but are associated with increased toxicity.

Purpose of the Study:

  • To evaluate the efficacy and safety of various chemotherapy regimens for hormone refractory prostate cancer.
  • To determine the impact of chemotherapy on palliative care and survival outcomes in HRPC patients.

Main Methods:

  • Review of randomized-controlled trials evaluating chemotherapy agents for HRPC.
  • Analysis of treatment outcomes including palliative efficacy, PSA response rates, toxicity, and survival.

Main Results:

  • Mitoxantrone combined with prednisone (or hydrocortisone) demonstrates palliative benefits in HRPC patients.
  • Estramustine and taxane regimens yield high PSA response rates but exhibit significant toxicity.
  • Recent studies indicate survival improvement with docetaxel-based chemotherapy regimens.

Conclusions:

  • Chemotherapy plays a role in managing hormone refractory prostate cancer, offering both palliative benefits and potential survival advantages.
  • Further research into chemotherapeutic agents is necessary to optimize quality of life and prolong survival for HRPC patients.

Related Experiment Videos